PathoVax
Baltimore
About PathoVax
PathoVax is a biotech start-up from Johns Hopkins commercializing RGVax, the world’s first low-cost Human Papillomavirus (HPV) vaccine targeting all clinically relevant types. Current vaccines target some cancer-causing HPVs and only focus on sexual transmitted types, resulting in low uptake due to the incomplete coverage and social stigma. Established animal studies have confirmed RGVax’s protection against all 15 oncogenic types and the added coverage against skin HPVs positions RGVax as a childhood vaccine, allowing unrivalled early market entry in a segment with superior uptake.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.0M
- Last round: Series Unknown (Aug 2018)
- Website: pathovax.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Health Care
Social Profiles
Canonical: https://fsome.com/organization/pathovax-144302 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.